Mike Nally is the Chief Executive Officer of Generate Biomedicines and is a CEO-Partner at Flagship Pioneering. Since joining Generate Biomedicines in 2021, Mike led the company’s $370 million Series B financing to advance its pioneering generative biology platform and secured its first research collaboration with Amgen, which includes discovering and creating protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.